EUVIMEDEUVIMED entdecken
Crossref

Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia

Laura Dery, Ilan Shimon, Yaron Rudman, Hiba Masri Iraqi, Shiri Kushnir, Tzipora Shochat, Odelia Cooper, Amit Akirov

Journal of Endocrinological Investigation · 2024

DOI: 10.1007/s40618-024-02492-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von Laura Dery und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Hyperprolactinemia, Breast Neoplasms, Dopamine Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperprolactinemiaBreast NeoplasmsDopamine AgonistsHumansFemaleAdultRetrospective StudiesMiddle AgedIncidenceRisk FactorsCase-Control StudiesProlactinFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

Breast Cancer; Dopamine Agonist; Hyperprolactinemia; Pituitary; Prolactinoma

Substanzen

Dopamine AgonistsProlactin

Autor:innen und Institutionen

  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Institute of Endocrinology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, 49100, Israel.
  • Research Authority, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
  • Biostatistics Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
  • Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. amit.akirov@gmail.com.

Zitieren

APA

Dery, L., Shimon, I., Rudman, Y., Iraqi, H. M., Kushnir, S., Shochat, T., Cooper, O., & Akirov, A. (2024). Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02492-2

Vancouver

Dery L, Shimon I, Rudman Y, Iraqi HM, Kushnir S, Shochat T, et al. Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia. Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02492-2

BibTeX
@article{Dery2024,
  author = {Dery, Laura and Shimon, Ilan and Rudman, Yaron and Iraqi, Hiba Masri and Kushnir, Shiri and Shochat, Tzipora and Cooper, Odelia and Akirov, Amit},
  title = {Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  doi = {10.1007/s40618-024-02492-2}
}
Kostenlos starten →